Shrink the tumor patients receive oral imatinib mesylate. Medical search. Frequent questions

Home page Questions and answers Statistics Donations Contact

Anatomy13

Cell Line, Tumor K562 Cells Philadelphia Chromosome Neoplastic Stem Cells Cells, Cultured Chromosomes, Human, Pair 9 Cell Line Stromal Cells Fibroblasts Myeloid Progenitor Cells Bone Marrow Skin Orbit

Organisms4

Mice, SCID Mice, Inbred BALB C Mice, Nude Mice, Inbred C57BL

Diseases60

Gastrointestinal Stromal Tumors Leukemia, Myelogenous, Chronic, BCR-ABL Positive Brain Neoplasms Leukemia, Myeloid, Chronic-Phase Wilms Tumor Gastrointestinal Neoplasms Blast Crisis Hypereosinophilic Syndrome Hypopigmentation Philadelphia Chromosome Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative Neoplasms Glioma Neuroendocrine Tumors Leukemoid Reaction Pasteurellosis, Pneumonic Carcinoid Tumor Bone Neoplasms Dermatofibrosarcoma Mastocytosis, Systemic Neoplasm Metastasis Fibromatosis, Aggressive Kidney Neoplasms Astrocytoma Germinoma Disease Progression Neoplasm Recurrence, Local Neoplasms, Germ Cell and Embryonal Leukemia, Myeloid, Accelerated Phase Glioblastoma Neoplasm, Residual Neoplasms, Experimental Testicular Neoplasms Lichenoid Eruptions Pasteurella Infections Meningioma Sarcoma, Ewing Pancreatic Neoplasms Skin Neoplasms Recurrence Breast Neoplasms Liver Neoplasms Primary Myelofibrosis Lung Neoplasms Histiocytoma, Malignant Fibrous Mammary Neoplasms, Experimental Neovascularization, Pathologic Spinal Cord Neoplasms Precursor Cell Lymphoblastic Leukemia-Lymphoma Scleroderma, Systemic Adenocarcinoma Fibrosis Chromosome Aberrations Disease Models, Animal Nerve Sheath Neoplasms Cattle Diseases Peritoneal Neoplasms Leukemia Graves Ophthalmopathy Osteosarcoma

Chemicals and Drugs50

Benzamides Piperazines Pyrimidines Fusion Proteins, bcr-abl Antineoplastic Agents Proto-Oncogene Proteins c-kit Protein Kinase Inhibitors Receptor, Platelet-Derived Growth Factor alpha Receptor, Platelet-Derived Growth Factor beta Tumor Markers, Biological Protein-Tyrosine Kinases Proto-Oncogene Proteins c-abl Receptors, Platelet-Derived Growth Factor Enzyme Inhibitors Tumor Necrosis Factor-alpha Neoplasm Proteins RNA, Messenger Thiazoles Pregnatrienes Proto-Oncogene Proteins c-sis Antigens, Neoplasm Hypertonic Solutions Harringtonines Bleomycin Interferon-alpha Hypotonic Solutions Tumor Suppressor Protein p53 mRNA Cleavage and Polyadenylation Factors Pyrroles Ketones Furans Tumor Suppressor Proteins Rifabutin Platelet-Derived Growth Factor Indoles STAT5 Transcription Factor Hydroxyurea Radiopharmaceuticals Stem Cell Factor Oncogene Proteins, Fusion Antigens, CD34 Etoposide P-Glycoprotein src-Family Kinases Antineoplastic Agents, Phytogenic Cisplatin Milk Proteins Proto-Oncogene Proteins c-akt Potassium Fluorodeoxyglucose F18

Analytical, Diagnostic and Therapeutic Techniques and Equipment44

Treatment Outcome Cytogenetic Analysis Remission Induction Disease-Free Survival Prognosis Survival Analysis Tumor Burden Antineoplastic Combined Chemotherapy Protocols Combined Modality Therapy Reverse Transcriptase Polymerase Chain Reaction Survival Rate Drug Approval Immunohistochemistry Drug Administration Schedule Follow-Up Studies Salvage Therapy Retrospective Studies Administration, Oral Tomography, X-Ray Computed Neoplasms, Experimental Neoplasm Staging Xenograft Model Antitumor Assays In Situ Hybridization, Fluorescence Blotting, Western Magnetic Resonance Imaging Treatment Failure Sensitivity and Specificity Inhibitory Concentration 50 Prospective Studies Neoadjuvant Therapy Mammary Neoplasms, Experimental Models, Biological Positron-Emission Tomography DNA Mutational Analysis Transplantation, Heterologous Polymerase Chain Reaction Reproducibility of Results Gene Expression Profiling Flow Cytometry Disease Models, Animal Blood Cell Count Transplantation, Homologous Transfection Kaplan-Meier Estimate

Phenomena and Processes30

Drug Resistance, Neoplasm Genes, abl Time Factors Philadelphia Chromosome Dose-Response Relationship, Drug Mutation Cell Proliferation Apoptosis Osmosis Phosphorylation Drug Synergism Signal Transduction Genes, Tumor Suppressor Osmotic Pressure Cell Division Cell Survival Cell Size Gene Expression Regulation, Leukemic Chromosomes, Human, Pair 9 Gene Expression Regulation, Neoplastic Tumor Microenvironment Sensitivity and Specificity Inhibitory Concentration 50 Algorithms Down-Regulation Chromosome Aberrations Blood Cell Count Gene Expression Osmolar Concentration Transfection

Disciplines and Occupations2

Immunohistochemistry Cytogenetics

Anthropology, Education, Sociology and Social Phenomena2

Drug Approval United States Food and Drug Administration

Technology, Industry, Agriculture2

Transportation Milk Proteins

Information Science2

Survival Rate Algorithms

Health Care13

Treatment Outcome Disease-Free Survival Survival Analysis Survival Rate Follow-Up Studies Retrospective Studies Housing, Animal Treatment Failure United States Food and Drug Administration Sensitivity and Specificity Prospective Studies Reproducibility of Results Kaplan-Meier Estimate

Anatomy Organisms Diseases Chemicals and Drugs Analytical, Diagnostic and Therapeutic Techniques and Equipment Phenomena and Processes Disciplines and Occupations Anthropology, Education, Sociology and Social Phenomena Technology, Industry, Agriculture Information Science Health Care

Benzamides Piperazines Pyrimidines Gastrointestinal Stromal Tumors Leukemia, Myelogenous, Chronic, BCR-ABL Positive Fusion Proteins, bcr-abl Antineoplastic Agents Proto-Oncogene Proteins c-kit Protein Kinase Inhibitors Receptor, Platelet-Derived Growth Factor alpha Brain Neoplasms Leukemia, Myeloid, Chronic-Phase Wilms Tumor Gastrointestinal Neoplasms Receptor, Platelet-Derived Growth Factor beta Blast Crisis Treatment Outcome Drug Resistance, Neoplasm Hypereosinophilic Syndrome Genes, abl Cell Line, Tumor Cytogenetic Analysis Tumor Markers, Biological Protein-Tyrosine Kinases Proto-Oncogene Proteins c-abl Hypopigmentation K562 Cells Time Factors Philadelphia Chromosome Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative Neoplasms Glioma Transportation Neuroendocrine Tumors Dose-Response Relationship, Drug Remission Induction Leukemoid Reaction Pasteurellosis, Pneumonic Disease-Free Survival Carcinoid Tumor Prognosis Survival Analysis Bone Neoplasms Mutation Receptors, Platelet-Derived Growth Factor Cell Proliferation Tumor Burden Antineoplastic Combined Chemotherapy Protocols Enzyme Inhibitors Dermatofibrosarcoma Tumor Necrosis Factor-alpha Combined Modality Therapy Reverse Transcriptase Polymerase Chain Reaction Survival Rate Mastocytosis, Systemic Neoplasm Metastasis Drug Approval Fibromatosis, Aggressive Kidney Neoplasms Neoplasm Proteins RNA, Messenger Immunohistochemistry Drug Administration Schedule Follow-Up Studies Thiazoles Pregnatrienes Astrocytoma Apoptosis Germinoma Salvage Therapy Proto-Oncogene Proteins c-sis Retrospective Studies Disease Progression Osmosis Antigens, Neoplasm Neoplasm Recurrence, Local Phosphorylation Neoplasms, Germ Cell and Embryonal Hypertonic Solutions Drug Synergism Harringtonines Signal Transduction Leukemia, Myeloid, Accelerated Phase Glioblastoma Administration, Oral Tomography, X-Ray Computed Bleomycin Interferon-alpha Neoplasm, Residual Neoplasms, Experimental Genes, Tumor Suppressor Osmotic Pressure Neoplastic Stem Cells Cell Division Testicular Neoplasms Neoplasm Staging Xenograft Model Antitumor Assays Cell Survival Hypotonic Solutions Lichenoid Eruptions

No FAQ available that match "shrink the tumor patients receive oral imatinib mesylate"